Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

518804

	registered interest
	date	18/05/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Funeral Payments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of the impact of Health Education England’s demand-led approach to the assessment of the number of consultant posts needed in highly specialist fields such as clinical pharmacology.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL98
	answer	answer is ministerial correction date of answer 25/05/2016 answer text <p>It is Health Education England’s responsibility to ensure that there is sufficient future supply of staff, including those needed in specialist fields, to meet the workforce requirements of the English health system.</p><p> </p><p>The Workforce Plan is built upon the needs of local employers, providers, commissioners and other stakeholders who, as members of its Local Education Training Boards (LETBs), shape the thirteen local plans.</p><p> </p><p>The Workforce Plan is predominately an aggregate of the local LETB plans, but the final national plan is only agreed with the advice and input of its clinical advisory groups and Patients’ Advisory Forum, as well as the Royal Colleges and other stakeholders.</p> answering member printed Lord Prior of Brampton question first answered 25/05/2016 13:52:12 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

753291

	registered interest
	date	18/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	2
	legislature	25277 pref label House of Lords
	question text	Her Majesty's Government whether they intend to ensure that Clinical Commissioning Groups are notified when a paediatric audiology service does not meet the standards for Improving Quality in Physiological Services accreditation following an assessment visit.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL979
	answer	answer is ministerial correction date of answer 20/07/2017 answer text <p>The Improving Quality in Physiological Services (IQIPS) accreditation scheme is run by the United Kingdom Accreditation Service (UKAS). The process of accreditation provides an independent assessment that a service meets the accreditation standards.</p><p> </p><p>It is the responsibility of the service to ensure that they conform to the standard before application to UKAS for accreditation. There is a pre-registration process within the scheme that enables all services to be able to do an effective gap analysis so that they should be at a point of conforming to the standard on making an application to UKAS. If during an assessment mandatory findings are raised which show non-conformity to any part of the standard then the service agrees appropriate improvement actions with the UKAS team to rectify these and prevent re-occurrence.</p><p> </p><p>The UKAS team base their recommendation for accreditation on the findings raised relating to the conformity to the standard, risk and whether the agreed improvement actions are appropriate and can be achieved within a three month close-out period. Therefore any findings raised must be cleared by the organisation if a positive recommendation for accreditation is to be granted.</p><p> </p><p>In <em>Commissioning Services for People with Hearing Loss: A framework for clinical commissioning groups</em>, published in July 2016, NHS England strongly encourages clinical commissioning groups to expect providers to have completed the IQIPS self-assessment tool and applied for accreditation with UKAS, and achieve accreditation within the duration of their contract.</p><p> </p><p>UKAS are supporting the NHS England business objective to increase the use of accreditation, and information about those services which have achieved accreditation is not held by the Department or NHS England, but is publicly available on the UKAS website.</p><p> </p><p>Information on clinical contracts is not held centrally by NHS England.</p> answering member printed Baroness Chisholm of Owlpen grouped question UIN HL887 HL889 HL890 HL891 question first answered 20/07/2017 14:50:44 answering member 4330 label Biography information for Baroness Chisholm of Owlpen
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

518803

	registered interest
	date	18/05/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prime Minister: Ministerial Policy Advisers
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what action they are taking to ensure that NICE guidance is followed in the use of faecal microbiota transplants in the treatment of recurrent Clostridium difficile infections.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL97
	answer	answer is ministerial correction date of answer 26/05/2016 answer text <p>The National Institute for Health and Care Excellence has produced guidance on faecal microbiota transplant for recurrent <em>Clostridium difficile</em> infection under the interventional procedure programme. This programme makes recommendations about the safety of the procedures and how well they work. However the guidance does not constitute a direction to National Health Service trusts to provide the interventions. Decisions about whether to provide a treatment are taken locally.</p> answering member printed Lord Prior of Brampton grouped question UIN HL94 question first answered 26/05/2016 16:29:01 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

76620

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neurofibromatosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what is the scale of neurofibromatosis Type 1 in the United Kingdom.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL962
	answer	answer is ministerial correction date of answer 14/07/2014 answer text <p>The number of people with neurofibromatosis type 1 (NF1) in England is estimated to number 11,267. The condition can be mild in some patients, manifesting itself only in patches of skin discolouration and soft benign bumps under the skin (neurofibromas), but for others NF1 causes more serious complications, including a rare form of cancer, curvature of the spine and nerve problems caused by more invasive neurofibromas.</p><p> </p><p>Since 1 April 2013, NHS England has been responsible for securing high quality care for all patients with complex NF1 as part of its specialised commissioning responsibilities. NHS England's NF1 service specification clearly sets out what needs to be in place for providers to offer evidence-based, safe and effective care, ensuring equity of access to a nationally consistent, high quality service. Specialist care is delivered by two designated centres based in Manchester (Central Manchester University Hospitals NHS Foundation Trust) and London (Guys and St. Thomas' NHS Foundation Trust, London) and these provide outreach support into other cities. The service is available to all patients with a suspected or confirmed diagnosis of NF1.</p><p> </p><p>The service specification can be viewed on the NHS England website at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf.</p> answering member printed Earl Howe grouped question UIN HL960 HL961 question first answered 14/07/2014 16:18:38 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

76619

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neurofibromatosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how they will ensure a co-ordinated response at local level for neurofibromatosis Type 1 sufferers.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL961
	answer	answer is ministerial correction date of answer 14/07/2014 answer text <p>The number of people with neurofibromatosis type 1 (NF1) in England is estimated to number 11,267. The condition can be mild in some patients, manifesting itself only in patches of skin discolouration and soft benign bumps under the skin (neurofibromas), but for others NF1 causes more serious complications, including a rare form of cancer, curvature of the spine and nerve problems caused by more invasive neurofibromas.</p><p> </p><p>Since 1 April 2013, NHS England has been responsible for securing high quality care for all patients with complex NF1 as part of its specialised commissioning responsibilities. NHS England's NF1 service specification clearly sets out what needs to be in place for providers to offer evidence-based, safe and effective care, ensuring equity of access to a nationally consistent, high quality service. Specialist care is delivered by two designated centres based in Manchester (Central Manchester University Hospitals NHS Foundation Trust) and London (Guys and St. Thomas' NHS Foundation Trust, London) and these provide outreach support into other cities. The service is available to all patients with a suspected or confirmed diagnosis of NF1.</p><p> </p><p>The service specification can be viewed on the NHS England website at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf.</p> answering member printed Earl Howe grouped question UIN HL960 HL962 question first answered 14/07/2014 16:18:38 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

76618

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neurofibromatosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to develop a national service framework for neurofibromatosis Type 1 sufferers.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL960
	answer	answer is ministerial correction date of answer 14/07/2014 answer text <p>The number of people with neurofibromatosis type 1 (NF1) in England is estimated to number 11,267. The condition can be mild in some patients, manifesting itself only in patches of skin discolouration and soft benign bumps under the skin (neurofibromas), but for others NF1 causes more serious complications, including a rare form of cancer, curvature of the spine and nerve problems caused by more invasive neurofibromas.</p><p> </p><p>Since 1 April 2013, NHS England has been responsible for securing high quality care for all patients with complex NF1 as part of its specialised commissioning responsibilities. NHS England's NF1 service specification clearly sets out what needs to be in place for providers to offer evidence-based, safe and effective care, ensuring equity of access to a nationally consistent, high quality service. Specialist care is delivered by two designated centres based in Manchester (Central Manchester University Hospitals NHS Foundation Trust) and London (Guys and St. Thomas' NHS Foundation Trust, London) and these provide outreach support into other cities. The service is available to all patients with a suspected or confirmed diagnosis of NF1.</p><p> </p><p>The service specification can be viewed on the NHS England website at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf.</p> answering member printed Earl Howe grouped question UIN HL961 HL962 question first answered 14/07/2014 16:18:37 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

518802

	registered interest
	date	18/05/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Burial and Cremation
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of the rate of uptake by the NHS of faecal microbiota transplants in the treatment of recurrent Clostridium difficile infections.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL96
	answer	answer is ministerial correction date of answer 26/05/2016 answer text <p>The National Institute for Health and Care Excellence (NICE) has produced guidance on faecal microbiota transplant for recurrent <em>Clostridium difficile</em> infection. NICE has recommended that the procedure is safe enough for use in the National Health Service, but no assessment of its cost effectiveness has been made by NICE.</p><p> </p><p>Data on the uptake by the NHS of faecal microbiota transplants in the treatment of recurrent <em>Clostridium difficile</em> is not collected centrally.</p> answering member printed Lord Prior of Brampton grouped question UIN HL95 question first answered 26/05/2016 16:25:27 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

76617

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Disability Aids
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the impact of the potential internal production of the report required under section 22 of the Chronically Sick and Disabled Persons Act 1970 on the identification of innovation opportunities, particularly for the manufacturing industry and small and medium-sized enterprises.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL959
	answer	answer is ministerial correction date of answer 17/07/2014 answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p><em>The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.</em></p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology, and this contract expired in June 2014. The annual cost was £72,268 (figure for final year). The contract was funded by the Department's Policy Research Programme.</p><p> </p><p>The Department has to deliver change in a climate of continuing fiscal challenge and constraint on public spending, and the approach to reporting on assistive technology research and development is aligned with this. The Department does not therefore plan to invite tenders for production of Section 22 reports from 2014-15 and will produce future reports on a smaller scale and of sufficient quality to meet the statutory requirement. This will be done in-house at no additional cost.</p><p> </p><p>As the Government will continue to meet the statutory requirement, no formal consultation on Section 22 has been undertaken or planned.</p><p> </p><p>Reports produced under Section 22, together with other sources of information about Government-funded assistive technology research (including published outputs, project databases, trial registers, websites and other information published by research funders and organisations carrying out research) will continue to make information available that can be used to support the identification of innovation opportunities and the identification and adoption of technology.</p><p> </p> answering member printed Earl Howe grouped question UIN HL897 HL898 HL899 HL900 HL901 HL902 HL957 HL958 question first answered 17/07/2014 11:49:08 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

76616

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Disability Aids
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what measures they intend to take in order to ensure that the potential internal production of the report required under section 22 of the Chronically Sick and Disabled Persons Act 1970 will not lead to a reduction in the quality of the report.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL958
	answer	answer is ministerial correction date of answer 17/07/2014 answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p><em>The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.</em></p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology, and this contract expired in June 2014. The annual cost was £72,268 (figure for final year). The contract was funded by the Department's Policy Research Programme.</p><p> </p><p>The Department has to deliver change in a climate of continuing fiscal challenge and constraint on public spending, and the approach to reporting on assistive technology research and development is aligned with this. The Department does not therefore plan to invite tenders for production of Section 22 reports from 2014-15 and will produce future reports on a smaller scale and of sufficient quality to meet the statutory requirement. This will be done in-house at no additional cost.</p><p> </p><p>As the Government will continue to meet the statutory requirement, no formal consultation on Section 22 has been undertaken or planned.</p><p> </p><p>Reports produced under Section 22, together with other sources of information about Government-funded assistive technology research (including published outputs, project databases, trial registers, websites and other information published by research funders and organisations carrying out research) will continue to make information available that can be used to support the identification of innovation opportunities and the identification and adoption of technology.</p><p> </p> answering member printed Earl Howe grouped question UIN HL897 HL898 HL899 HL900 HL901 HL902 HL957 HL959 question first answered 17/07/2014 11:49:08 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

76615

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Assistive Technology: Research
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the impact of producing internally at the Department of Health the report required under section 22 of the Chronically Sick and Disabled Persons Act 1970 on the quality of research into areas of innovative assistive technology and the adoption of such technology; and what measures they intend to take prevent a decrease in both research into and adoption of such technology.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL957
	answer	answer is ministerial correction date of answer 17/07/2014 answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p><em>The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.</em></p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology, and this contract expired in June 2014. The annual cost was £72,268 (figure for final year). The contract was funded by the Department's Policy Research Programme.</p><p> </p><p>The Department has to deliver change in a climate of continuing fiscal challenge and constraint on public spending, and the approach to reporting on assistive technology research and development is aligned with this. The Department does not therefore plan to invite tenders for production of Section 22 reports from 2014-15 and will produce future reports on a smaller scale and of sufficient quality to meet the statutory requirement. This will be done in-house at no additional cost.</p><p> </p><p>As the Government will continue to meet the statutory requirement, no formal consultation on Section 22 has been undertaken or planned.</p><p> </p><p>Reports produced under Section 22, together with other sources of information about Government-funded assistive technology research (including published outputs, project databases, trial registers, websites and other information published by research funders and organisations carrying out research) will continue to make information available that can be used to support the identification of innovation opportunities and the identification and adoption of technology.</p><p> </p> answering member printed Earl Howe grouped question UIN HL897 HL898 HL899 HL900 HL901 HL902 HL958 HL959 question first answered 17/07/2014 11:49:08 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath